Citi upgraded MorphoSys to Neutral from Sell with a EUR 68 price target after Novartis announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MOR: